Human Fas/TNFRSF6/CD95 Antibody Summary
Accession # P25445
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of Fas/TNFRSF6/CD95 in HEK293 Human Cell Line Transfected with Human Fas/TNFRSF6/CD95 and eGFP by Flow Cytometry. HEK293 human embryonic kidney cell line transfected with either (A) Human Fas/TNFRSF6/CD95 or (B) irrelevant transfectants and eGFP was stained with Mouse Anti-Human Fas/TNFRSF6/CD95 Monoclonal Antibody (Catalog # MAB326) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB002). View our protocol for Staining Membrane-associated Proteins.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Fas, also known as APO-1, CD95, and TNFRSF6, was originally identified as a cell-surface protein which binds to monoclonal antibodies that were cytolytic for various human cell lines. In the new TNF Receptor superfamily nomenclature, Fas is referred to as TNFRSF6. Human Fas cDNA encodes a 325 amino acid (aa) residue type 1 membrane protein that belongs to the TNF and NGF receptor family. Alternatively spliced cDNAs encoding multiple Fas isoforms, including a soluble form of Fas lacking the transmembrane domain, have also been identified. Fas is highly expressed in epithelial cells, hepatocytes, activated mature lymphocytes, virus-transformed lymphocytes, and other tumor cells. Fas expression has also been detected in mouse thymus, liver, heart, lung, kidney and ovary. The ligand for Fas (FasL) has been identified and shown to be a member of the TNF family of type 2 membrane proteins. FasL is predominantly expressed by activated T‑lymphocytes, NK cells, and in tissues with immune-privileged sites. Soluble FasL can be produced by proteolysis of membrane-associated Fas.
Ligation of Fas by FasL or anti-Fas antibody has been shown to induce apoptotic cell death in Fas-bearing cells. Fas plays a role in the down-regulation of the immune reaction and has been shown to be a key mediator of activation-induced death of activated T‑lymphocytes. Fas-mediated cell death has also been shown to be important for the deletion of activated or autoreactive B‑lymphocytes. Besides the perforin/granzyme-based mechanism, the Fas system has been identified as the alternate pathway for CTL‑mediated cytotoxicity. FasL has also been shown to function in immunological privileged sites by killing infiltrating Fas-bearing lymphocytes and inflammatory cells.
- Nagata, S. and P. Golstein (1995) Science 267:1449.
- Nagata, S. (1997) Cell 88:355.
- Parijs, L. and A.K. Abbas (1996) Current Opinion in Immunol. 8:355.
- Green, D.R. and C.F. Ware (1997) Proc. Natl. Acad. Sci. USA 94:5986.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human Fas/TNFRSF6/CD95 Antibody
Average Rating: 5 (Based on 1 Review)
Have you used Human Fas/TNFRSF6/CD95 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image